The European medicines Agency (EMA) approved the use of vaginal rings with dapivirine for the prevention of HIV infection in women older than 18 years living in developing countries. This is the first means of long-term protection from HIV infection, says MedicalXpress.
Regulators approved the vaginal ring made from silicone elastomer and contains dapivirine (non-nucleoside reverse transcriptase inhibitor). Its period of usage for 1 month, and the replacement of the ring a woman can hold its own. Such remedies relevant to women in poor countries.
Studies of the vaginal ring was held in Malawi, South Africa, Uganda and Zimbabwe. As the results, the vast majority of participants voluntarily installed the vaginal ring and observe the mode of its replacement. Data collected shows that the application of a preventive treatment helped reduce the risk of infection by 27%. However, the researchers note, if you do not take into account data about patients who were not rules for the use of the ring, the probability of infection on the background of vaginal rings is reduced by 37%. The maximum efficiency of the ring (reducing the risk of infection by 56%) was observed among women over the age of 21.